Antibody-drug conjugates (ADCs) have significantly changed the therapeutic landscape in BC, with FDA-approved ADCs targeting HER2/3, including trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) [25,62]. The gene discussed is ERBB2; the disease is breast cancer.